Phase 3 Oncology Deal Benchmarks

Median Upfront

$721M

Range: $472M - $929M

Total Deal Value

$3.1B

Range: $2.4B - $3.9B

Royalty Rate

16.1% - 24.6%

Tiered up to 28.6%

Dev Milestones

$243M

Range: $189M - $301M

Model Your Deal

Market Analysis

Phase 3 oncology licensing deals carry a median total deal value of $3.1B, with upfront payments ranging from $472M to $929M. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 23% to upfront and 77% to milestones.

The oncology landscape at the phase 3 stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $243M, regulatory milestones contribute $849M, and commercial milestones reach $1.3B. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.

Royalty rates for phase 3 oncology deals range from 16.1% to 24.6% at the base tier, with high-tier escalation to 28.6%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 3 oncology deals?

Phase 3 oncology deals average $721M in upfront payments, ranging from $472M to $929M. The upfront allocation of 23% of total deal value reflects the clinical stage risk profile.

How are phase 3 oncology deal milestones structured?

Milestones account for approximately 77% of total deal value. Development milestones ($243M) represent the largest component, followed by commercial milestones ($1.3B) and regulatory milestones ($849M).

What royalty rates are typical for phase 3 oncology licensing?

Base royalty rates range from 16.1% to 24.6%, with tiered escalation to 20.1%-28.6% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 3 Oncology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Oncology Deals

Phase 1 Oncology Deals

Phase 3 Neurology Deals

Phase 3 Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?